Advanced search

Topotecan, an active drug in the second-line treatment of epithelial ovarian cancer: Results of a large European phase II study.

(1996) JOURNAL OF CLINICAL ONCOLOGY. 14(12). p.3056-3061
Author
Organization

Citation

Please use this url to cite or link to this publication:

Chicago
CREEMERS, GJ, G BOLIS, M GORE, G SCARFONE, AJ LACAVE, JP GUASTALLA, R DESPAX, et al. 1996. “Topotecan, an Active Drug in the Second-line Treatment of Epithelial Ovarian Cancer: Results of a Large European Phase II Study.” Journal of Clinical Oncology 14 (12): 3056–3061.
APA
CREEMERS, G., BOLIS, G., GORE, M., SCARFONE, G., LACAVE, A., GUASTALLA, J., DESPAX, R., et al. (1996). Topotecan, an active drug in the second-line treatment of epithelial ovarian cancer: Results of a large European phase II study. JOURNAL OF CLINICAL ONCOLOGY, 14(12), 3056–3061.
Vancouver
1.
CREEMERS G, BOLIS G, GORE M, SCARFONE G, LACAVE A, GUASTALLA J, et al. Topotecan, an active drug in the second-line treatment of epithelial ovarian cancer: Results of a large European phase II study. JOURNAL OF CLINICAL ONCOLOGY. 1996;14(12):3056–61.
MLA
CREEMERS, GJ, G BOLIS, M GORE, et al. “Topotecan, an Active Drug in the Second-line Treatment of Epithelial Ovarian Cancer: Results of a Large European Phase II Study.” JOURNAL OF CLINICAL ONCOLOGY 14.12 (1996): 3056–3061. Print.
@article{191211,
  author       = {CREEMERS, GJ and BOLIS, G and GORE, M and SCARFONE, G and LACAVE, AJ and GUASTALLA, JP and DESPAX, R and FAVALLI, G and KREINBERG, R and VANBELLE, S and HUDSON, I and VERWEIJ, J and HUININK, WWT},
  issn         = {0732-183X},
  journal      = {JOURNAL OF CLINICAL ONCOLOGY},
  language     = {eng},
  number       = {12},
  pages        = {3056--3061},
  title        = {Topotecan, an active drug in the second-line treatment of epithelial ovarian cancer: Results of a large European phase II study.},
  volume       = {14},
  year         = {1996},
}